KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

nhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; Kosaka et al., 2006; Rudin e...

Full description

Bibliographic Details
Main Authors: Krall, Elsa B, Munoz, Diana M, Ilic, Nina, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Redig, Amanda J, Gainor, Justin F, Williams, Juliet A, Asara, John M, Janne, Pasi A, Shaw, Alice T, McDonald III, Robert E, Engelman, Jeffrey A, Stegmeier, Frank, Schlabach, Michael R, Wang, Belinda, Raghavan, Srivatsan, Aguirre, Andrew J., Kim, Jong Wook, Doench, John Gerard, Hahn, William
Other Authors: Broad Institute of MIT and Harvard
Format: Article
Language:en_US
Published: eLife Sciences Publications, Ltd. 2017
Online Access:http://hdl.handle.net/1721.1/109867
https://orcid.org/0000-0001-5367-2546

Internet

http://hdl.handle.net/1721.1/109867
https://orcid.org/0000-0001-5367-2546

Similar Items